People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Biotechnology, Pharmaceuticals, Other Health Care, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Janux Therapeutics, Inc. | — | Biotechnology | Series D+ | $192.4M | $4.0B | 2020 |
| Enlaza Therapeutics, Inc. | — | Pharmaceuticals | Series C | $134.6M | $87.7M | 2021 |
| AristaMD, Inc. | — | Other Health Care | Series B | $71.2M | $136.5M | 2015 |
| Synthorx, Inc. | — | Biotechnology | Series B | $34.7M | $1.1B | 2016 |
| Arialys Therapeutics, Inc. | — | Biotechnology | Series A | $29.1M | $49.2M | 2022 |
| AeroRx Therapeutics, Inc. | — | Pharma | Series A | $10.4M | $30.7M | 2025 |
| Cellular Approaches, Inc. | — | Biotechnology | Seed | $2.6M | $113.7M | 2016 |
Tighe Reardon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tighe Reardon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jay Lichter | 4 | 7 |
| Douglas Downs | 2 | 6 |
| Court Turner | 2 | 6 |
| Jay Lichter, Ph.D. | 2 | 5 |
| ANDREW LEVIN | 1 | 17 |
| Peter Thompson | 1 | 16 |
| James Topper | 1 | 12 |
| Brant Heise | 1 | 10 |
| Shelley Chu | 1 | 10 |
| Ed Hurwitz | 1 | 9 |
| Stephen Squinto | 1 | 8 |
| Laura Shawver | 1 | 6 |
| Thomas Cooper | 1 | 6 |
| John Kuelper | 1 | 6 |
| Craig Cimini | 1 | 5 |
| Sheila Gujrathi | 1 | 5 |
| Vickie L. Capps | 1 | 3 |
| Michael Scarbrough | 1 | 3 |
| David Eichler | 1 | 2 |
| Sanford Madigan | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.